Addex Therapeutics (ADXN) EBT Margin (2019 - 2025)
Addex Therapeutics (ADXN) posted EBT Margin of 739347.58% for Q4 2025, down 13833.51% sequentially from 5306.25% in Q3 2025, and down 66044632.0% YoY from N/an in Q4 2024.
Addex Therapeutics (ADXN) EBT Margin (2019 - 2025) Analysis & Trends
Addex Therapeutics has reported EBT Margin for 7 years, with the latest figure at 739347.58% in Q4 2025.
- Quarterly EBT Margin fell 66044632.0% year-over-year to 739347.58% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 21102.8% (down 1928840.0% YoY) and the FY2025 annual result came in at 22829.93%, down 2161506.0% from the prior year.
- EBT Margin retreated to 739347.58% in Q4 2025 per ADXN's latest filing, from 5306.25% in the prior quarter.
- Over five years, EBT Margin peaked at 1071.63% in Q4 2022 and troughed at 739347.58% in Q4 2025.
- A 5-year average of 46524.46% and a median of 794.25% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2021 and 2025: EBT Margin jumped 1162409 bps in 2021, then tumbled 66044632 bps in 2025.
- Over 5 years, EBT Margin stood at 140.31% in 2021, then jumped by 864 bps to 1071.63% in 2022, then slumped by 155 bps to 585.21% in 2023, then plunged by 13383 bps to 78901.26% in 2024, then tumbled by 837 bps to 739347.58% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 739347.58%, 5306.25%, and 78901.26% for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 12.09% |
| 10 | Addex Therapeutics | 511.09 Mn | 511.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -739,347.58% |
| Sep 30, 2025 | -5,306.25% |
| Dec 31, 2024 | -78,901.26% |
| Sep 30, 2024 | -2,837.40% |
| Jun 30, 2024 | -1,263.70% |
| Mar 31, 2024 | -1,343.09% |
| Dec 31, 2023 | -585.21% |
| Sep 30, 2023 | -216.86% |
| Jun 30, 2023 | -82.65% |
| Mar 31, 2023 | -73.87% |
| Dec 31, 2022 | 1,071.63% |
| Sep 30, 2022 | -1,003.29% |
| Jun 30, 2022 | -3,938.42% |
| Mar 31, 2022 | -2,174.15% |
| Dec 31, 2021 | -140.31% |
| Sep 30, 2021 | -527.59% |
| Jun 30, 2021 | -472.51% |
| Mar 31, 2021 | -297.76% |
| Dec 31, 2020 | -60.90% |
| Sep 30, 2020 | -12,151.68% |